Calidi Biotherapeutics, Inc.
CLDI
$1.56
-$0.18-10.35%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.46% | 19.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.89% | 25.73% | |||
| Operating Income | -11.89% | -25.73% | |||
| Income Before Tax | -13.80% | -22.05% | |||
| Income Tax Expenses | 33.33% | 0.00% | |||
| Earnings from Continuing Operations | -13.81% | -22.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -39.47% | 49.02% | |||
| Net Income | -14.62% | -21.70% | |||
| EBIT | -11.89% | -25.73% | |||
| EBITDA | 0.34% | -26.55% | |||
| EPS Basic | -275.42% | 31.30% | |||
| Normalized Basic EPS | -277.03% | 31.41% | |||
| EPS Diluted | -275.42% | 31.30% | |||
| Normalized Diluted EPS | -277.03% | 31.41% | |||
| Average Basic Shares Outstanding | -69.47% | 77.17% | |||
| Average Diluted Shares Outstanding | -69.47% | 77.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||